Abstract 126P
Background
Colorectal cancer (CRC) is the fourth leading cause of cancer death in the world. Immune response to tumors can control tumor growth or contribute to an immunosuppressive environment that promotes tumor progression. The prognostic importance of infiltrating subsets of T lymphocytes in CRC has been widely accepted, and subsequently led to be criteria of the Immunoscore. The role of infiltrating B lymphocytes remains controversial and in matters of prognostic effect has to be explored.
Methods
FFPE tissue samples from pCRC and CRC liver metastasis (LM) of 99 patients were stained immunohistochemically for CD20, the densities of CD20+ cells was assessed in tumor center (TC), inner margin (IM), outer margin (OM) and peritumor (PT) from pCRC and synchronous and metachronous liver metastasis by using QuPath software. These were evaluated for association and correlation with histopathologic features by the Fridman test and Spearman correlation analysis. And prognostic significance of CD20+ cells, for time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS) was evaluated using Kaplan-Meier and Cox regression analyses.
Results
High cell density of CD20+ B cells in PT of pCRC (HR=0.45 (0.22-0.93, p=0.031)), in IM (HR=0.49 (0.24-0.99, p=0.047)) and in PT (HR=0.42 (0.22-0.81, p=0.009)) of liver metastasis were associated with a longer OS of patients in the synchronous group. High density of CD 20+ immune cells in PT of LM correlated with a longer DFS of patients in the metachronous group (HR=0.35 (0.13-0.89, p=0.027)). Good response to treatment is associated with longer DFS (HR=2.98 (1.38-6.43, p=0.005)) of patients in the metachronous group after liver metastasis resection. The patients without nodal invasion in the metachronous group had longer TTR (HR=2.29 (1.14-4.60, p=0.020)) after liver surgery.
Conclusions
Our results suggested that high cell density of CD20+ in PT of pCRC and IM and PT of LM indicated better outcomes of patients. Response to treatment and lower nodal stage have positive prognostic impact on CRC patients.
Legal entity responsible for the study
Jindřich Fínek.
Funding
AZV 20b.
Disclosure
All authors have declared no conflicts of interest.